Combined 18F-NaF and 18F-FDG PET/CT in the evaluation of sarcoma patients

Tatianie Jackson, Camila Mosci, Rie Von Eyben, Erik Mittra, Kristen Ganjoo, Sandip Biswal, Sanjiv Sam Gambhir, Andrei Iagaru

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose The combined administration of 18F-NaF and 18F-FDG in a single PET/CT scan has the potential to improve patient convenience and cancer detection. Here we report the use of this approach for patients with sarcomas. Patients and Methods This is a retrospective review of 21 patients (12 men, 9 women; age, 19-66 years) with biopsy-proven sarcomas who had separate 18F-NaF PET/CT, 18F-FDG PET/CT, and combined 18F-NaF/18F-FDG PET/CT scans for evaluation of malignancy. Two board-certified nuclear medicine physicians and 1 board-certified musculoskeletal radiologist were randomly assigned to review the scans. Results were analyzed for sensitivity and specificity, using linear regression and receiver operating characteristics. Results A total of 13 patients had metastatic disease on 18F-NaF PET/CT, 18F-FDG PET/CT, and combined 18F-NaF/18F-FDG PET/CT. Skeletal disease was more extensive on the 18F-NaF PET/CT scan than on the 18F-FDG PET/CT in 3 patients, whereas in 1 patient, 18F-FDG PET/CT showed skeletal disease and the 18F-NaF PET/CT was negative. Extraskeletal lesions were detected on both 18F-FDG and combined 18F-NaF/18F-FDG PET/CT in 20 patients, with 1 discordant finding in the lung. Conclusions The combined 18F-NaF/18F-FDG PET/CT scan allows for accurate evaluation of sarcoma patients. Further evaluation of this proposed imaging modality is warranted to identify the most suitable clinical scenarios, including initial treatment strategy and evaluation of response to therapy.

Original languageEnglish (US)
Pages (from-to)720-724
Number of pages5
JournalClinical Nuclear Medicine
Volume40
Issue number9
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Sarcoma
Nuclear Medicine
ROC Curve
Linear Models
Neoplasms
Physicians
Biopsy
Sensitivity and Specificity
Lung
Positron Emission Tomography Computed Tomography

Keywords

  • <sup>18</sup>F-FDG
  • <sup>18</sup>F-NaF
  • Combined
  • PET/CT
  • Sarcoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Jackson, T., Mosci, C., Von Eyben, R., Mittra, E., Ganjoo, K., Biswal, S., ... Iagaru, A. (2015). Combined 18F-NaF and 18F-FDG PET/CT in the evaluation of sarcoma patients. Clinical Nuclear Medicine, 40(9), 720-724. https://doi.org/10.1097/RLU.0000000000000845

Combined 18F-NaF and 18F-FDG PET/CT in the evaluation of sarcoma patients. / Jackson, Tatianie; Mosci, Camila; Von Eyben, Rie; Mittra, Erik; Ganjoo, Kristen; Biswal, Sandip; Gambhir, Sanjiv Sam; Iagaru, Andrei.

In: Clinical Nuclear Medicine, Vol. 40, No. 9, 01.01.2015, p. 720-724.

Research output: Contribution to journalArticle

Jackson, T, Mosci, C, Von Eyben, R, Mittra, E, Ganjoo, K, Biswal, S, Gambhir, SS & Iagaru, A 2015, 'Combined 18F-NaF and 18F-FDG PET/CT in the evaluation of sarcoma patients', Clinical Nuclear Medicine, vol. 40, no. 9, pp. 720-724. https://doi.org/10.1097/RLU.0000000000000845
Jackson, Tatianie ; Mosci, Camila ; Von Eyben, Rie ; Mittra, Erik ; Ganjoo, Kristen ; Biswal, Sandip ; Gambhir, Sanjiv Sam ; Iagaru, Andrei. / Combined 18F-NaF and 18F-FDG PET/CT in the evaluation of sarcoma patients. In: Clinical Nuclear Medicine. 2015 ; Vol. 40, No. 9. pp. 720-724.
@article{bf74536a05a1473dbe2d95d317995dbf,
title = "Combined 18F-NaF and 18F-FDG PET/CT in the evaluation of sarcoma patients",
abstract = "Purpose The combined administration of 18F-NaF and 18F-FDG in a single PET/CT scan has the potential to improve patient convenience and cancer detection. Here we report the use of this approach for patients with sarcomas. Patients and Methods This is a retrospective review of 21 patients (12 men, 9 women; age, 19-66 years) with biopsy-proven sarcomas who had separate 18F-NaF PET/CT, 18F-FDG PET/CT, and combined 18F-NaF/18F-FDG PET/CT scans for evaluation of malignancy. Two board-certified nuclear medicine physicians and 1 board-certified musculoskeletal radiologist were randomly assigned to review the scans. Results were analyzed for sensitivity and specificity, using linear regression and receiver operating characteristics. Results A total of 13 patients had metastatic disease on 18F-NaF PET/CT, 18F-FDG PET/CT, and combined 18F-NaF/18F-FDG PET/CT. Skeletal disease was more extensive on the 18F-NaF PET/CT scan than on the 18F-FDG PET/CT in 3 patients, whereas in 1 patient, 18F-FDG PET/CT showed skeletal disease and the 18F-NaF PET/CT was negative. Extraskeletal lesions were detected on both 18F-FDG and combined 18F-NaF/18F-FDG PET/CT in 20 patients, with 1 discordant finding in the lung. Conclusions The combined 18F-NaF/18F-FDG PET/CT scan allows for accurate evaluation of sarcoma patients. Further evaluation of this proposed imaging modality is warranted to identify the most suitable clinical scenarios, including initial treatment strategy and evaluation of response to therapy.",
keywords = "<sup>18</sup>F-FDG, <sup>18</sup>F-NaF, Combined, PET/CT, Sarcoma",
author = "Tatianie Jackson and Camila Mosci and {Von Eyben}, Rie and Erik Mittra and Kristen Ganjoo and Sandip Biswal and Gambhir, {Sanjiv Sam} and Andrei Iagaru",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/RLU.0000000000000845",
language = "English (US)",
volume = "40",
pages = "720--724",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Combined 18F-NaF and 18F-FDG PET/CT in the evaluation of sarcoma patients

AU - Jackson, Tatianie

AU - Mosci, Camila

AU - Von Eyben, Rie

AU - Mittra, Erik

AU - Ganjoo, Kristen

AU - Biswal, Sandip

AU - Gambhir, Sanjiv Sam

AU - Iagaru, Andrei

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose The combined administration of 18F-NaF and 18F-FDG in a single PET/CT scan has the potential to improve patient convenience and cancer detection. Here we report the use of this approach for patients with sarcomas. Patients and Methods This is a retrospective review of 21 patients (12 men, 9 women; age, 19-66 years) with biopsy-proven sarcomas who had separate 18F-NaF PET/CT, 18F-FDG PET/CT, and combined 18F-NaF/18F-FDG PET/CT scans for evaluation of malignancy. Two board-certified nuclear medicine physicians and 1 board-certified musculoskeletal radiologist were randomly assigned to review the scans. Results were analyzed for sensitivity and specificity, using linear regression and receiver operating characteristics. Results A total of 13 patients had metastatic disease on 18F-NaF PET/CT, 18F-FDG PET/CT, and combined 18F-NaF/18F-FDG PET/CT. Skeletal disease was more extensive on the 18F-NaF PET/CT scan than on the 18F-FDG PET/CT in 3 patients, whereas in 1 patient, 18F-FDG PET/CT showed skeletal disease and the 18F-NaF PET/CT was negative. Extraskeletal lesions were detected on both 18F-FDG and combined 18F-NaF/18F-FDG PET/CT in 20 patients, with 1 discordant finding in the lung. Conclusions The combined 18F-NaF/18F-FDG PET/CT scan allows for accurate evaluation of sarcoma patients. Further evaluation of this proposed imaging modality is warranted to identify the most suitable clinical scenarios, including initial treatment strategy and evaluation of response to therapy.

AB - Purpose The combined administration of 18F-NaF and 18F-FDG in a single PET/CT scan has the potential to improve patient convenience and cancer detection. Here we report the use of this approach for patients with sarcomas. Patients and Methods This is a retrospective review of 21 patients (12 men, 9 women; age, 19-66 years) with biopsy-proven sarcomas who had separate 18F-NaF PET/CT, 18F-FDG PET/CT, and combined 18F-NaF/18F-FDG PET/CT scans for evaluation of malignancy. Two board-certified nuclear medicine physicians and 1 board-certified musculoskeletal radiologist were randomly assigned to review the scans. Results were analyzed for sensitivity and specificity, using linear regression and receiver operating characteristics. Results A total of 13 patients had metastatic disease on 18F-NaF PET/CT, 18F-FDG PET/CT, and combined 18F-NaF/18F-FDG PET/CT. Skeletal disease was more extensive on the 18F-NaF PET/CT scan than on the 18F-FDG PET/CT in 3 patients, whereas in 1 patient, 18F-FDG PET/CT showed skeletal disease and the 18F-NaF PET/CT was negative. Extraskeletal lesions were detected on both 18F-FDG and combined 18F-NaF/18F-FDG PET/CT in 20 patients, with 1 discordant finding in the lung. Conclusions The combined 18F-NaF/18F-FDG PET/CT scan allows for accurate evaluation of sarcoma patients. Further evaluation of this proposed imaging modality is warranted to identify the most suitable clinical scenarios, including initial treatment strategy and evaluation of response to therapy.

KW - <sup>18</sup>F-FDG

KW - <sup>18</sup>F-NaF

KW - Combined

KW - PET/CT

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84939510056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939510056&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000845

DO - 10.1097/RLU.0000000000000845

M3 - Article

VL - 40

SP - 720

EP - 724

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 9

ER -